首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126352

抗菌藥物抗藥性（AMR）診斷市場：策略性洞察與預測（2026-2035）

AMR Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月05日 | 出版商:

Knowledge Sourcing Intelligence | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計抗菌素抗藥性 (AMR) 診斷市場將從 2026 年的 64.3 億美元成長到 2035 年的 155.9 億美元，複合年成長率為 10.3%。

抗菌藥物抗藥性診斷市場正經歷重大變革，其驅動力在於抗菌藥物抗藥性威脅的日益加劇以及全球對快速、準確診斷資訊以指導標靶治療的需求。這一市場演變的特點是模式轉移，從傳統的基於培養的方法轉向分子診斷、次世代定序和整合藥敏試驗平台。由於不恰當的抗生素選擇會導致不良的臨床結果並加速抗藥性的發展，醫療系統越來越需要在治療過程的早期階段提供診斷資訊。因此，快速診斷不僅是一種檢測工具，更成為合理使用抗菌藥物（AMS）的關鍵要素。分子診斷、自動化和人工智慧的融合使得病原體識別和抗藥性檢測的速度更快。醫療基礎設施的現代化正在推動診斷技術的應用，透過能夠整合病原體識別、藥敏試驗和數位化報告的自動化平台來實現這一目標。監管機構持續認可診斷技術在對抗抗菌藥物抗藥性方面的關鍵作用，並鼓勵製造商即使在微生物抗藥性模式變化的情況下，也要保持其產品的臨床相關性。隨著對快速表現型檢測、基因組監測平台和人工智慧診斷工具的大量投資，抗菌素抗藥性診斷技術正成為現代感染疾病控制和公共衛生措施的基石。

市場促進因素

抗生素抗藥性日益加劇是抗菌藥物抗藥性診斷市場的主要驅動力。由於抗藥性病原體會降低標準抗生素療法的療效，抗生素抗藥性造成了巨大的臨床負擔。隨著經驗性治療在嚴重感染疾病的可靠性下降，醫療專業人員越來越需要快速的診斷資訊。病原體鑑定延遲會導致治療準確性降低，並增加不合理使用抗生素的可能性。診斷設備製造商正在擴展結合病原體鑑定和抗藥性檢測的平台，以支援更快速的治療決策。這種轉變推動了醫院和公共衛生機構對先進抗菌藥物抗藥性診斷的需求成長，抗菌藥物抗藥性診斷的應用也穩步擴大。抗菌藥物風險管理（IPSS）計畫的擴展透過增加對快速診斷的需求，進一步加速了市場成長。隨著醫療系統努力減少不必要的抗生素使用，IPSS計畫在提高醫療品質方面發揮核心作用。由於多種病原體類別的抗藥性持續上升，醫院越來越關注抗生素處方模式。傳統的診斷流程往往會延遲治療方案的最佳化，因此，人們越來越需要更快、更實用的檢測結果。醫療機構正在採用快速診斷技術，以便早期療育並調整治療方案。這種轉變提升了抗菌藥物抗藥性診斷在常規臨床工作流程中的策略價值。分子診斷技術的日益普及推動了對更快病原體檢測的需求。與傳統的基於培養的方法相比，分子診斷技術能夠更快地檢測病原體。由於臨床醫生需要及時了解嚴重感染疾病的信息，臨床檢查室擴大採用基於PCR和多重檢測的平台。雖然傳統的培養方法對於藥物敏感性測定仍然很重要，但檢測結果的時效性為在急診護理環境中的操作帶來了挑戰。製造商正在開發高度自動化的分子診斷系統，這些系統在保持分析性能的同時，簡化了檢查室操作。加強監測和公共衛生措施正透過基礎設施投資支持市場擴張。各國政府和國際組織已將抗菌藥物抗藥性視為一項重大的公共衛生威脅。各國的監測計畫正在擴巨量資料收集工作，以便更好地了解整個醫療系統中的抗藥性模式。

市場限制因素

大量資本投入限制了資源有限的小規模醫療機構和檢查室採用先進的分子診斷平台。高昂的資金投入對小規模機構而言構成障礙。某些快速診斷技術的保險覆蓋範圍有限，即使其臨床有效性已得到證實，也降低了購買這些技術的獎勵。保險覆蓋範圍的區域差異給診斷服務提供者帶來不確定性，並限制了患者的就醫途徑。熟練的微生物學家、分子診斷專家和生物資訊學專家的短缺阻礙了複雜診斷流程的推廣應用。這種專業知識的匱乏限制了先進抗菌素抗藥性診斷技術的擴充性。不同司法管轄區法規的複雜性也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

市場定義和範圍
抗菌素抗藥性：疾病與公共衛生概述
抗菌藥物抗藥性診斷技術的演變
主要市場趨勢
全球抗菌素抗藥性負擔分析
抗藥性病原體的流行情況
已確診患者族群的分析
測試數量分析
目前診斷和臨床管理狀況
市場規模表現分析
市場預測分析

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

藥物抗藥性診斷領域的新興技術
產品創新趨勢
臨床試驗分析
管道分析
次世代定序（NGS）的整合
人工智慧與生物資訊學的融合
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求

第8章：抗菌素抗藥性診斷市場：展望分析

分析：按技術平台
分析：依生物標記類型
分析：依樣本類型
分析：透過臨床應用
分析：透過調查方法
分析：按最終使用者環境

第9章：抗菌素抗藥性診斷市場：細分市場分析

依產品類型
- 裝置
- 試劑和耗材
- 軟體和分析解決方案
透過技術
- 培養法藥敏試驗
- 聚合酵素鏈鎖反應（PCR）
- 次世代定序（NGS）
- 基於微陣列的診斷
- 質譜（MALDI-TOF）
- 等溫放大技術
- 其他分子診斷技術
依病原體類型
- 細菌病原體
- 真菌病原體
- 病毒病原體
抗性機制
- - BETA-內醯胺類抗生素抗藥性
- 碳青黴烯抗藥性
- 耐甲氧西林
- 萬古黴素抗藥性
- 多重抗藥性
依樣本類型
- 血
- 尿
- 呼吸系統檢體
- 傷口檢體
- 糞便檢體
- 其他檢體類型
最終用戶
- 醫院
- 臨床實驗室
- 學術研究機構
- 公共衛生研究所
- 其他最終用戶

第10章：抗菌素抗藥性診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：抗菌藥物抗藥性診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
中國
日本
印度
韓國
澳洲
巴西
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
bioMerieux SA
Becton, Dickinson and Company
Danaher Corporation（Cepheid, Beckman Coulter）
QIAGEN NV
Bruker Corporation
Abbott Laboratories
Sysmex Corporation
Accelerate Diagnostics, Inc.
T2 Biosystems, Inc.
OpGen, Inc.
Revvity, Inc.
Oxford Nanopore Technologies plc
Seegene Inc.

第14章：抗菌素抗藥性診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009063

The AMR Diagnostics Market is anticipated to grow at a CAGR of 10.3% from USD 6.43 billion in 2026 to USD 15.59 billion in 2035.

The AMR diagnostics market is undergoing significant transformation driven by the escalating threat of antimicrobial resistance and the global imperative for rapid, accurate diagnostic information to guide targeted therapy. The market's evolution is characterized by a paradigm shift from conventional culture-based methods toward molecular diagnostics, next-generation sequencing, and integrated susceptibility testing platforms. Healthcare systems are increasingly demanding diagnostic information much earlier in the treatment pathway because inappropriate antibiotic selection contributes to poorer clinical outcomes and accelerates resistance development. Rapid diagnostics are therefore becoming an integral component of antimicrobial stewardship rather than solely laboratory testing tools. The convergence of molecular diagnostics, automation, and artificial intelligence is enabling faster pathogen identification and resistance detection. Healthcare infrastructure modernization is increasing diagnostic adoption through automated platforms capable of integrating organism identification with susceptibility testing and digital reporting. Regulatory organizations continue to recognize diagnostics as a critical component of AMR mitigation strategies, encouraging manufacturers to maintain clinical relevance despite evolving microbial resistance patterns. The market is witnessing significant investment in rapid phenotypic testing, genomic surveillance platforms, and AI-enabled interpretation tools, positioning AMR diagnostics as a cornerstone of modern infectious disease management and public health preparedness.

Market Drivers

The growing burden of antimicrobial resistance represents the primary driver for the AMR diagnostics market. AMR is creating a significant clinical burden because resistant pathogens reduce the effectiveness of standard antimicrobial therapies. Healthcare providers are increasingly requiring rapid diagnostic information as empirical treatment becomes less reliable for severe infections. Delayed pathogen identification limits therapeutic precision and increases the probability of inappropriate antibiotic utilization. Diagnostic manufacturers are expanding platforms that combine organism identification with resistance detection to support faster treatment decisions. This shift strengthens demand for advanced AMR diagnostics across hospital and public health settings, resulting in sustained growth in AMR diagnostic utilization. The expansion of antimicrobial stewardship programs is further accelerating market growth through increased demand for rapid diagnostics. Antimicrobial stewardship programs have become a core component of healthcare quality initiatives because healthcare systems seek to reduce unnecessary antibiotic exposure. Hospitals are increasingly monitoring antimicrobial prescribing patterns as resistance rates continue to rise across multiple pathogen categories. Conventional diagnostic workflows often delay treatment optimization, creating pressure for faster and more actionable laboratory results. Healthcare institutions are adopting rapid diagnostic technologies that enable earlier antimicrobial intervention and therapy adjustment. This transition increases the strategic value of AMR diagnostics within routine clinical workflows. The increasing adoption of molecular diagnostics is driving demand for faster pathogen detection. Molecular diagnostic technologies provide faster pathogen detection than traditional culture-based approaches. Clinical laboratories are integrating PCR-based and multiplex testing platforms because clinicians require timely information for critical infections. Conventional culture remains important for susceptibility determination, yet turnaround time limitations create operational constraints in acute care environments. Manufacturers are developing highly automated molecular systems that simplify laboratory implementation while maintaining analytical performance. Strengthening surveillance and public health initiatives is supporting market expansion through infrastructure investment. Governments and international organizations recognize AMR as a major public health threat. National surveillance programs are expanding data collection efforts to improve understanding of resistance patterns across healthcare systems.

Market Restraints

High capital investment requirements limit adoption of advanced molecular diagnostic platforms among smaller healthcare facilities and resource-constrained laboratories. The significant financial investment required for advanced platforms creates barriers for smaller facilities. Limited reimbursement coverage for certain rapid diagnostic technologies reduces purchasing incentives despite demonstrated clinical benefits. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Shortages of skilled microbiologists, molecular diagnosticians, and bioinformatics specialists constrain implementation of complex diagnostic workflows. The shortage of specialized personnel limits the scalability of advanced AMR diagnostics. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated diagnostic ecosystems and automation. Culture-based susceptibility testing remains the clinical reference standard because it directly evaluates antimicrobial effectiveness against isolated pathogens. Demand is increasingly shifting toward PCR, NGS, MALDI-TOF, microarray, and isothermal amplification technologies because clinicians require faster diagnostic information. Conventional culture methods often create treatment delays that prolong empirical antibiotic use and increase healthcare costs. Molecular and sequencing technologies are reducing turnaround times while expanding the ability to identify resistance genes and emerging resistance mechanisms. The segment analysis reveals that bacterial pathogens represent the largest focus area because bacterial AMR continues driving significant healthcare burdens worldwide. Healthcare systems are increasingly monitoring fungal resistance as invasive fungal infections become more common among immunocompromised patient populations. Resistance mechanisms including beta-lactam resistance, carbapenem resistance, methicillin resistance, vancomycin resistance, and multidrug resistance represent critical testing targets. Blood, urine, and respiratory samples constitute major specimen types for AMR testing. Hospitals represent the leading end-user segment, with clinical diagnostic laboratories and public health laboratories expanding testing capacity. The integration of AI is becoming increasingly important because diagnostic datasets are becoming more complex as laboratories integrate molecular testing, sequencing, and advanced susceptibility platforms. Technology providers are incorporating AI and machine learning capabilities that support automated result interpretation and clinical decision support.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized molecular and sequencing providers. Thermo Fisher Scientific occupies a strategically important position because it combines molecular diagnostics, sequencing technologies, laboratory instruments, reagents, and bioinformatics capabilities within a single ecosystem, expanding genomic and molecular diagnostic capabilities that simplify laboratory operations while supporting high-throughput testing requirements. Roche maintains a strong competitive position because of its extensive expertise in molecular diagnostics, infectious disease testing, and healthcare data integration, expanding molecular diagnostic solutions that provide clinically actionable information while supporting laboratory efficiency. bioMerieux is strategically distinct because of its longstanding focus on clinical microbiology, infectious disease diagnostics, and antimicrobial susceptibility testing, enhancing automated microbiology solutions that improve laboratory efficiency while delivering actionable susceptibility information. BD occupies an important position because it combines microbiology expertise, automated laboratory systems, and infectious disease diagnostics, expanding automation capabilities that improve laboratory productivity while supporting diagnostic accuracy. Danaher, through Cepheid and Beckman Coulter, provides molecular diagnostics, microbiology solutions, automation technologies, and laboratory workflow management capabilities, expanding molecular testing capabilities that support rapid pathogen identification and resistance detection. QIAGEN differentiates itself through its strong focus on molecular diagnostics, sample preparation technologies, and bioinformatics solutions that support infectious disease testing and resistance monitoring, expanding syndromic testing and molecular detection capabilities. Companies are pursuing product portfolio expansion through innovation in rapid phenotypic testing, NGS platforms, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and public health organizations are increasing, driven by the need for surveillance and stewardship. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding. Mergers and acquisitions are occurring as larger players seek to expand market presence and technology capabilities.

Short Conclusion

The AMR diagnostics market is positioned for sustained growth driven by the convergence of antimicrobial resistance burden, stewardship programs, and technological innovation. The transition from conventional culture-based methods toward integrated molecular and genomic platforms represents a fundamental shift in infectious disease diagnostics. While challenges related to high costs, reimbursement variability, and workforce shortages persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with AMR diagnostics evolving into a cornerstone of modern infectious disease management, supporting rapid pathogen identification, resistance detection, and public health surveillance across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. AMR Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Antimicrobial Resistance (AMR): Disease and Public Health Overview
3.3 Evolution of AMR Diagnostic Technologies
3.4 Key Market Trends
3.5 Global AMR Burden Analysis
3.6 Prevalence of Drug-Resistant Pathogens
3.7 Diagnosed Patient Population Analysis
3.8 Testing Volume Analysis
3.9 Current Diagnostic and Clinical Management Landscape
3.10 Historical Market Size Analysis (2021-2025)
3.11 Market Forecast Analysis (2026-2035)

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies in AMR Diagnostics
6.2 Product Innovation Trends
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Next-Generation Sequencing (NGS) Integration
6.6 AI and Bioinformatics Integration
6.7 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. AMR Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker Type
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology
8.6 Analysis by End User Environment

9. AMR Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product Type
- 9.1.1 Instruments
- 9.1.2 Reagents & Consumables
- 9.1.3 Software & Analytics Solutions
9.2 By Technology
- 9.2.1 Culture-Based Susceptibility Testing
- 9.2.2 Polymerase Chain Reaction (PCR)
- 9.2.3 Next-Generation Sequencing (NGS)
- 9.2.4 Microarray-Based Diagnostics
- 9.2.5 Mass Spectrometry (MALDI-TOF)
- 9.2.6 Isothermal Amplification Technologies
- 9.2.7 Other Molecular Diagnostic Technologies
9.3 By Pathogen Type
- 9.3.1 Bacterial Pathogens
- 9.3.2 Fungal Pathogens
- 9.3.3 Viral Pathogens
9.4 By Resistance Mechanism
- 9.4.1 ?-Lactam Resistance
- 9.4.2 Carbapenem Resistance
- 9.4.3 Methicillin Resistance
- 9.4.4 Vancomycin Resistance
- 9.4.5 Multidrug Resistance
9.5 By Sample Type
- 9.5.1 Blood
- 9.5.2 Urine
- 9.5.3 Respiratory Samples
- 9.5.4 Wound Samples
- 9.5.5 Stool Samples
- 9.5.6 Other Sample Types
9.6 By End User
- 9.6.1 Hospitals
- 9.6.2 Clinical Diagnostic Laboratories
- 9.6.3 Academic & Research Institutes
- 9.6.4 Public Health Laboratories
- 9.6.5 Other End Users